Chem. J. Chinese Universities ›› 2009, Vol. 30 ›› Issue (5): 903.

Previous Articles     Next Articles

Searching for Novel Lead Compounds of α1-AR Antagonists: Synthesis, Bioassays and 3D-QSAR of 2-[4-(Aryloxyalkyl)-piperazin-1-yl]benzo[d]oxazole Compounds

LI Jia-Bin1, LIU Hai-Chun1, ZHANG Li4, WANG Tao3, JIANG Zhen-Zhou3, XIA Lin2*   

    1. Department of Inorganic Chemistry,
    2. Department of Medicinal Chemistry,
    3. New Drug Screening Center, China Pharmaceutical University, Nanjing 210009, China;
    4. Shanghai Mass Spectrometry Center, Shanghai Institute of Organic Chemistry, Chinese Academy of Science, Shanghai 200032, China
  • Received:2008-11-18 Online:2009-05-10 Published:2009-05-10
  • Contact: XIA Lin, E-mail: phenopro@cpu.edu.cn

Abstract:

Benign prostatic hyperplasia(BPH) is a pathological disorder in the aged men that causes voiding difficulties and thus impacts the quality of life. α1-AR antagonists are clinically used for the treatment of BPH. Aimed at searching for the novel α1-adrenoceptor antagonists, eight target compounds bearing 2-(piperazin-1-yl)benzo[d]oxazole scaffold were designed from our lead compound wb5c and synthesized from 5-chloro-2-aminophenol and substituted phenols via condensation, chloration and amination, Williamson ether synthesis and substitution etc.. All target compounds were identified by ESI-MS, IR, 1H NMR and HRMS. Functional bioassays showed that they had moderate antagonistic activities against α1-AR. The CoMFA model was constructed for 2-(piperazin-1-yl)benzo[d]oxazole derivertives via SYBYL software package, q2=0.430, r2=0.907, fractions of steric and electrostatic fields were 0.465 and 0.535, respectively. 3D-QSAR analysis leads to insight into further structural optimization.

Key words: Benign prostatic hyperplasia(BPH), α1-Adrenoceptor, Antagonists, Benzoxazole, Piperazine, CoMFA model

TrendMD: